The Financial Post reports in its Wednesday edition that Tilray Brands' big bet on legal cannabis is proving so overoptimistic it is now relying on the alcohol market it once aimed to disrupt. A Canadian Press dispatch to the Post says that a long-awaited easing in U.S. cannabis laws, known as rescheduling, is still elusive, leaving in place suffocating restrictions on sales due to marijuana's classification alongside drugs including LSD and heroin. That has led cannabis companies to find other businesses, including alcohol and hemp, undercutting boasts like Tilray's in its debut 2019 filing that it would capture spending from brewers, distillers and wineries. "Cannabis operators in the U.S. are doing everything they can to generate cash flow and bridge until we get rescheduling," said Scott Fortune, Roth MKM managing director. "If we don't get rescheduling, we'll see further elimination, consolidation of many retailers, brands and operators within the industry." To avoid that fate, companies such as Tilray have sought more legitimate businesses like the sale of booze and hemp to stay alive. In the fiscal quarter that ended in May, the company more than doubled alcohol sales from a year earlier to $76.7-million (U.S.).